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Bevacizumab, a humanized monoclonal antibody (mAb) targeting to the vascular
endothelial growth factor (VEGF), has been widely used in clinical practice for the
treatment of multiple cancers. Bevacizumab was mostly produced by the mammalian
cell expression system. We here reported the first plant-derived Bevacizumab by
using transgenic rice callus as an alternative gene expression system. Codon-
optimized Bevacizumab light chain (BLC) and Bevacizumab heavy chain (BHC) genes
were designed, synthesized as a polyprotein with a 2A self-cleavage linker peptide
from the Foot-and-mouth disease virus, cloned into a plant binary vector under a
constitutive maize ubiquitin promoter, and transformed into rice nuclear genome through
Agrobacterium-mediated transformation. Southern blot and western blot analyses
confirmed the integration and expression of BLC and BHC genes in transgenic rice
callus. Enzyme-linked immunosorbent assay (ELISA) analysis indicated that the rice-
derived Bevacizumab mAb was biologically active and the recombinant mAb was
expressed at high levels (160.7–242.8 mg/Kg) in transgenic rice callus. The mAb was
purified by using protein A affinity chromatography and the purified antibody was tested
for its binding affinity with its target human VEGF (hVEGF) antigen by ELISA. Rice
callus produced Bevacizumab and a commercial Bevacizumab (Avastin) were shown to
have similar binding affinity to hVEGF. These results indicated that rice callus produced
Bevacizumab could have similar biological activity and might potentially be used as a
cost-effective biosimilar molecule in future cancer treatment.
Keywords: Bevacizumab, monoclonal antibody (mAb), plant transformation, 2A self-cleavage peptide, plant made
antibody, rice
INTRODUCTION
Plants including the whole body, specific tissues or organs and plant-derived suspension cells
are considered as attractive and competitive platforms for recombinant protein production.
Compared with Escherichia coli and mammalian cells, plant-based production systems have been
demonstrated to have many advantages. First, plant-based production systems are more flexible,
as well as easier to operate, manage, and scale up, and thus can decrease the production cost of
recombinant proteins to a great extent. Second, plants, similar to mammalian cells, are able to
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perform post-translational modification of recombinant proteins
such as glycosylation, and thus additional cost for in vitro
protein modifications can be avoided (Frenzel et al., 2013;
Sil and Jha, 2014; Kolotilin et al., 2015). Third, long-term
continuous recombinant protein production can be realized in
plant platforms because transgenes can be stably integrated
into the nuclear genome of host plants, faithfully inherited,
and expressed in later generations. Furthermore, plant-derived
recombinant proteins may be safer than those from E. coli or
mammalian cells because the risk of contamination with human
pathogens, which is always a concern when using mammalian
cells as a bioreactor, can be well circumvented by plant-based
production systems (Thie et al., 2008; Ni and Chen, 2009;
Merlin et al., 2014). Because of these properties, various bioactive
pharmaceutical proteins have been produced in plants since first
expression of a human growth hormone in transgenic tobacco
and sunflower callus tissue (Barta et al., 1986), and expression
of antibodies, vaccines, hormones, growth factors, and cytokines
(De Muynck et al., 2010; Desai et al., 2010; Xu et al., 2011; Huang
and McDonald, 2012).
Monoclonal antibodies (mAbs) are protein complexes
containing four subunits with two identical light chains (LC)
and two identical heavy chains (HC). MAbs are important
in biological research, clinical diagnosis, and recently
immunotherapy for various diseases and cancer (De Muynck
et al., 2010). Unlike other single chain recombinant proteins, the
production of mAbs requires simultaneous expression of two
genes coding for both LC and HC, and the correct folding of
four polypeptides linked by disulphide bonds. The discovery that
plant can efficiently express and correctly assemble functional
antibodies (Hiatt et al., 1989) have made plants an alternative
antibody production system, and since then, many recombinant
antibodies have been produced in various plants, including moss
(Decker and Reski, 2008), algae (Franklin and Mayfield, 2005),
and higher plants (Stoger et al., 2005; De Muynck et al., 2010; Xu
et al., 2011, 2012; Schillberg et al., 2013).
Previously, the LC and HC genes of a mAb were expressed
in two different expression cassettes on one T-DNA region of
a vector, or expressed separately in individual vectors which
were co-transformed to the same plant, or expressed in different
transgenic plants which were cross-fertilized to produce the
functional antibody (De Muynck et al., 2010; Ko, 2014). Because
the two genes are expressed separately, it is difficult to control
their relative expression level even though identical regulatory
elements are used. In fact, most of the previous reports have
produced unbalanced LC and HC in both transgenic plants and
mammalian cells (Voss et al., 1995; Law et al., 2006; De Muynck
et al., 2010; Chng et al., 2015). A varied LC:HC ratio is usually
unfavorable for the folding of functional mAbs, and affects both
the level and quality of mAbs (Schlatter et al., 2005; Law et al.,
2006; Lee et al., 2009; Ho et al., 2013b). The use of internal
ribosome entry site (IRES) to translate two polypeptides (LC and
HC) from one mRNA also results in an unbalanced expression
because of the lower efficiency of the IRES directed downstream
gene expression by a cap-independent translation mechanism
(Hennecke et al., 2001; Ho et al., 2012, 2013a,b). In contrast, the
use of 2A peptide from the Aphthovirus Foot-and-mouth disease
virus (FMDV) for high level mAb expression has been reported in
both the human embryonic kidney 293 and the Chinese hamster
ovary (CHO) cells (Fang et al., 2005; Chng et al., 2015), but this
strategy for mAb expression in transgenic plant system has not
been reported so far.
Bevacizumab is a humanized mAb that targets to the
vascular endothelial growth factor (VEGF) antigen (Presta et al.,
1997; Ferrara et al., 2005), which is widely over expressed
in a variety of human solid tumors and plays a key role
in tumor angiogenesis (Ellis and Hicklin, 2008; Goel and
Mercurio, 2013; Domigan et al., 2015). Bevacizumab neutralizes
VEGFs, prevents their interactions with VEGFR-1 and VEGFR-2
receptors, and thus blocks the downstream signal transductions
for tumor angiogenesis (Wang et al., 2004). Bevacizumab is
derived from the murine VEGF mAb A4.6.1. It has 93%
human and 7% murine sequence, and has similar biochemical
and pharmacologic properties to the original murine mAb. It
neutralizes all isoforms of human VEGF (hVEGF) with high
affinity and inhibits VEGF-induced proliferation of endothelial
cells and tumor angiogenesis, but with reduced immunogenicity
and longer circular half-life as compared to the murine antibody
(Gerber and Ferrara, 2005). It has been widely applied in
clinical practice of metastatic colorectal cancer, glioblastoma,
non-small-cell lung cancer, metastatic kidney cancer, advanced
cervical cancer, platinum-resistant ovarian cancer (Giantonio,
2006; Ali et al., 2008; Tonini et al., 2013; Tewari et al., 2014;
Liu and Matulonis, 2015; Mason, 2015)1. Bevacizumab (Avastin)
is approved by the US Food and Drug Administration for
clinical use in cancer therapy (Bellmunt, 2007; Pal et al.,
2014).
Although increasing evidence suggests the great potency of
Bevacizumab for various disease therapies, there are still some
obstacles which limit its widespread applications (Hayashi et al.,
2014). One of the shortcomings is the high cost of Bevacizumab-
mediated therapy. The high cost of Bevacizumab is greatly
influenced by its production, which is solely dependent on
mammalian expression systems (Makino et al., 2011; Spadiut
et al., 2013).
In this study, we reported the first plant made Bevacizumab
by using transgenic rice callus as a gene expression system.
Rice is both a main stuff crop and a model plant for
biological studies because of its small genome and the
high efficient gene transformation system. Rice seeds and
suspension cultures have been reported as good systems for
the production of many high value bioactive proteins (Kim
et al., 2008; He et al., 2011; Kuo et al., 2013; Corbin et al.,
2016; Fujiwara et al., 2016). Codon-optimized Bevacizumab LC
and HC genes were designed, synthesized as a polyprotein
with a 2A self-cleavage linker peptide from the FMDV,
cloned into a plant binary vector under a constitutive maize
ubiquitin promoter, and transformed into rice nuclear genome
through Agrobacterium-mediated transformation. High levels of
biologically functional Bevacizumab were expressed and purified
by affinity chromatography. An enzyme-linked immunosorbent
assay (ELISA) binding assay showed that the rice expressed
1http://www.avastin.com/patient
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Bevacizumab and the commercial Avastin had similar binding
affinity to the VEGF target.
MATERIALS AND METHODS
Plant Materials
Rice (Oryza sativa var. japonica cv. Nipponbare) was used in this
study. Dehusk mature healthy seeds were washed with Milli-Q
water followed by 70% (v/v) ethanol for 30 s and then immersed
into 1.5% sodium hypochlorite for 30 min with vigorous shaking.
After being washed with sterilized Milli-Q water three times, the
seeds were placed on N6 medium (Chu et al., 1975) supplemented
with 2 mg/L 2,4-dichlorophenoxyacetic acid (N6D medium) at
28◦C in the darkness for 3 weeks in order to induce callus
from mature embryo. The obtained calli were subcultured every
3 weeks and prepared for subsequent Agrobacterium-mediated
transformation.
Construction of Plant Binary Vector
The LC and HC peptide sequences of Bevacizumab were obtained
from DrugBank database2. Genes coding for the Bevacizumab
light chain (BLC) and Bevacizumab heavy chain (BHC; GenBank,
KX119516 and KX119517) were optimized by an online codon
optimizer software3 using the characteristics of rice codon usage
bias4, based on the amino acid sequences of Bevacizumab
(Figures 1A,B). An endoplasmic reticulum (ER) retention signal
peptide (KDEL) was added to the C-termini of both BLC and
BHC for targeted expression of the recombinant proteins to ER
(Figure 1C).
To make a polyprotein of the BLC and BHC, a 2A sequence
(QLLNFDLLKLAGDVESNPGP) from FMDV (Donnelly et al.,
2001) was inserted between the BHC and BLC (Figures 1B,C).
A GSG peptide linker was inserted immediately preceding the 2A
sequence to improve the cleavage efficiency (Chng et al., 2015).
All the coding sequences were synthesized and placed under
a maize ubiquitin promoter and cloned into a plant binary
vector pUN1390 with PacI and MluI to make pUNBevaHL
and pUNBevaHL-KDEL (Figures 1B,C). pUNBevaHL-KDEL
differed from pUNBevaHL in the presence of the ER retention
sequences on both BLC and BHC chains.
Plant Transformation
Agrobacterium-mediated transformation was performed based
on the method of Nishimura et al. (2006). Recombinant
binary vectors were introduced into the Agrobacterium strain
EHA105 by freeze–thaw method (Weigel and Glazebrook, 2006).
The resulted Agrobacteria were cultured in lysogeny broth
(LB) liquid medium supplemented with 50 mg/L kanamycin
and 50 mg/L rifampicin at 28◦C with 220 rpm of agitation
overnight. These cultures were centrifuged and re-suspended
in AAM medium (Nishimura et al., 2006) containing 100 µM
acetosyringone, to make OD600 of the Agrobacterium suspension
2http://www.drugbank.ca/drugs/DB00112
3http://genomes.urv.es/OPTIMIZER/
4http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=311553
in the range of 0.05–0.10 for rice transformation. The newly
induced rice calli were dried with sterilized filter paper, kept
in Agrobacterium culture for 15 min with short agitation,
dried again with sterilized filter paper and finally placed on
co-cultivation medium at 28◦C in darkness for 3 days. The
resulted calli were then transferred onto selection medium
(N6D medium supplemented with 500 mg/L cefotaxime and
50 mg/L hygromycin B) and incubated at 28◦C in darkness
until the appearance of hygromycin B-resistant calli. After
three rounds of 3-week subculture on selection medium, the
hygromycin B-resistant calli were confirmed by southern blot
analysis (Supplementary Method S1), and regenerated according
to the method of Nishimura et al. (2006).
Western Blot
Total protein was extracted from calli of wild type and
selected transgenic rice lines. Calli were ground with a
mortar and pestle in liquid nitrogen. The resulting fine
powder was added to an equal volume of extraction buffer
(200 mM Tris–HCl, pH 8.0, 100 mM NaCl, 400 mM
sucrose, 10 mM ethylenediaminetetraacetic acid [EDTA], 1 mM
phenylmethylsulfonyl fluoride, 0.05% Tween 20), mixed gently,
and incubated on ice for 10 min. Samples were centrifuged
twice at 13,000 rpm for 10 min at 4◦C. Then 25 µg of
protein extracts were mixed with sodium dodecyl sulfate (SDS)
loading buffer, separated on a 10% SDS polyacrylamide gel
electrophoresis (PAGE) under reducing (boiled for 5 min
with 5% 2-mercaptoethanol) or non-reducing conditions, and
immunoblotted onto a polyvinylidene difluoride membrane
(Millipore Corporation, USA). The membrane were blocked for
2 h at room temperature with 3% (w/v) bovine serum albumin
(BSA) in 1× phosphate-buffered saline (PBS) containing 0.1%
(v/v) Tween-20 (PBST, 137 mM NaCl, 2.7 mM KCl, 8.1 mM
Na2HPO3, 1.5 mM KH2PO3, pH7.5) and probed for 2 h at
room temperature with peroxidase-conjugated affinipure goat
anti-human IgG (LC+HC) antibody (ProteinTech Group, USA)
diluted in blocking buffer [1× PBST with 3% (w/v) BSA] at a ratio
of 1:5000. The blotted membrane was washed three times with 1×
PBST and signals were developed by using a FUJI Medical X-ray
film (Fujifilm, Japan). A commercial Bevacizumab mAb from
Roche (Avastin, Lot No: H0129; Roche Pharma, Switzerland) was
used as a positive control.
Assuming that there is a range in which Western blot image
intensity is linearly proportional to protein concentration, the
relative expression of BLC and BHC can be determined by
analyzing the image intensity. Western blot images were analyzed
by an ImageJ program5 to determine the density of the BLC
and BHC bands of each transgenic line. The BLC:BHC ratio was
calculated by dividing the density of BLC by that of BHC.
Biological Activity of Rice-Derived
Bevacizumab
Biological activities of the rice-derived Bevacizumab from
transgenic rice callus were detected using an ELISA Kit
(SHIKARI Q-BEVA, Matriks Biotechnology Co. Ltd., Turkey).
5https://imagej.nih.gov/ij/index.html
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FIGURE 1 | T-DNA regions of constructs for rice transformation. (A) pUNBHLC construct with Bevacizumab LC (BLC) and HC (BHC) genes expressed in two
expression cassette; (B) pUNBevaHL construct with BLC and BHC expressed as a polyprotein linked with a FMDV 2A self-cleavage peptide; (C) pUNBevaHL-KDEL
construct with BLC and BHC expressed as a polyprotein as in (B), but a KDEL ER retention peptide sequence was added to the C-termini of the coding regions of
both BLC and BHC genes. Lysogeny broth (LB) and RB denote the left and right borders of the T-DNA region of the binary vector. TNos and T35S are terminators of
the Agrobacterium nopaline synthase gene and the CaMV 35S expression cassette, respectively. 2A is the self-cleavage peptide from foot-and-mouth disease virus,
and KDEL is the ER retention signal peptide. Two EcoRI (E) restriction enzyme digestion sites are indicated on pUNBevaHL and pUNBevaHL-KDEL constructs in
(B,C), and the ∼3 kb fragments flanked by the two EcoRI sites are indicated. The bars under pUNBevaHL construct (B) show the positions of HptII and BLC probes
used in Southern blot analysis.
The standards and samples were diluted at 1:100 using assay
buffer supplied in the kit, and were incubated in pre-coated
microtiter plate with hVEGF at 25◦C for 1 h. After being washed
three times with 1× PBST, a biotin labeled hVEGF was added
to the microtiter plate and incubated at 25◦C for 1 h. Following
1 h incubation, the wells were washed three times with 1×
PBST, and then a streptavidin conjugated horseradish peroxidase
(HRP) was added and incubated at 25◦C for 0.5 h. Then, the
wells were washed three times with 1× PBST and the bound
enzymatic activity was detected by adding a TMB (3,3′,5,5′-
tetramethylbenzidine) substrate solution. After incubation at
25◦C for 20 min, the substrate reaction was stopped by adding
a TMB stop solution into each well and the plates were read at a
wavelength of 450 nm in a microplate reader (BioTek, USA).
Quantification of Rice-Derived
Bevacizumab
A standard curve was produced by using the commercial
Bevacizumab at concentrations of 0, 3, 10, 30, and 100 µg/mL.
The mAb concentration in mg/Kg fresh weight (FW) in each
transgenic rice sample was calculated by comparing the OD450
reading to the prepared Bevacizumab standard curve. Three
replicates were measured for each sample and the data were
statistically analyzed.
Antibody Purification
Total soluble proteins were extracted from 50 g calli of two
transgenic lines (UNBevaHL-3-15 and UNBevaHL-KDEL-5)
as described before. Extracted proteins were filtered through
0.45 µm filters and loaded onto HiTrap Protein A HP columns
(GE Healthcare) pre-equilibrated with the binding buffer (0.02 M
sodium phosphate buffer, pH 7.0). Five column volumes of
binding buffer were used to wash the columns, and the mAbs
bound to protein A were eluted with the elution buffer (0.1
M Glycine-HCl, pH 2.7), collected into tubes containing one-
fifth volume of 1 M Tris–HCl (pH 9.0) to bring to pH 7.0. The
obtained mAbs were concentrated by ultrafiltration (molecular
weight cut-off, 30 kDa, Millipore, USA), quantified by ELISA as
described before, and then used for analyses of binding activities
and glycosylation. The purity of mAbs was analyzed by running
in a non-reducing SDS-PAGE followed by a Coomassie blue
staining.
VEGF Binding Affinity Assay
The binding affinity of purified rice-derived Bevacizumab to
its antigen was assessed by using a VEGF antigen binding
ELISA. The antigen hVEGF (11066-HNAH, Sino Biological Inc,
Beijing, China) solution in 1× PBS (50 µL, 0.5 µg/mL) was
coated onto 96-well microtiter plates (Nunc R©Model No. 4-42404,
Roskilde, Denmark) overnight at 4◦C. The wells were washed
five times with 200 µL of 1× PBST between each step to
completely remove unbound material. The wells were blocked
with 200 µL 1% BSA (w/v) in 1× PBS at 25◦C for 2 h. The
purified mAbs were serially diluted to concentrations of 0.0041–
9.0 µg/mL in 1× PBS. One hundred microliters of each diluted
solution was loaded into the wells, and incubated for 2 h at
25◦C. A commercial Bevacizumab was used as a reference, 1×
PBS buffer was used as the negative control. After washing,
bound antibodies to VEGF were incubated with 50 µL 1% BSA
in 1× PBS containing 1 µg/mL goat-derived HRP-conjugated
anti-human IgG (HC+LC) antibody (ProteinTech Group, USA).
One hundred microliters of TMB substrate solution was added to
each well, and the reaction was stopped after 20 min incubation
at 25◦C. The absorbance at 450 nm was read using a Microplate
Reader (BioTek, USA). All samples were assayed in triplicates.
N-glycan Analysis
The rice-derived Bevacizumab was purified as described
previously, digested with trypsin, and extracted from gel pieces
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according to Kolarich et al. (2006). The subsequent fractionation
of the peptides by capillary reversed-phase chromatography
and detection by a quadrupole time-of-flight Ultima Global
(Waters) mass spectrometer were performed according to Van
Droogenbroeck et al. (2007). The mass spectrometer data of
tryptic peptides were analyzed against the in silico-generated
tryptic digestion of the Bevacizumab amino acid sequence using
the Peptide Mass program6. Based on the tryptic peptide data
sets, tryptic glycopeptide data sets were generated by the addition
of glycan mass increments to the masses of the identified
glycopeptides.
Statistical Analysis
ELISA data were subjected to one-way analyses of variance with
OriginPro8 (Version8E, Origin Lab Corporation, MA, USA) and
presented as means± standard error of three replicates.
RESULTS
Construction and Expression of
Bevacizumab mAb in Transgenic Rice
To efficiently produce the recombinant mAb, we designed two
strategies for the BLC and BHC gene expression. In one design,
the BLC and BHC genes were expressed separately in two
gene expression cassettes both driven by the maize ubiquitin
promoter (Figure 1A). In the other design, the BLC and BHC
were expressed as a polyprotein gene linked by a FMDV 2A
self-cleavage peptide (Donnelly et al., 2001), which can be self-
processed to release the BLC and BHC proteins (Figure 1B). To
avoid plant-specific glycosylation in expressed proteins, an ER
retention signal (KDEL) was added to the C-termini of both the
BLC and BHC proteins (Figure 1C).
The three constructs were introduced into rice nuclear
genome by Agrobacterium-mediated transformation. Transgenic
calli were selected on medium supplemented with hygromycin B
based on the expression of the HptII selection marker gene. Stable
transgenic lines were confirmed by Southern blot analysis using
full-length BLC and hptII as probes. Fourteen transgenic events
were confirmed and the copy numbers of each transgenic line
were revealed. Among them, four transgenic lines had a single
copy transgene, six lines had two copies, and the rest of lines had
three or more copies (Supplementary Figure S1). Transgenic calli
were regenerated to produce transgenic rice plants which showed
normal phenotypes similar to the wild type rice (Supplementary
Figure S2).
Selected transgenic rice callus lines were further tested by SDS-
PAGE analysis to confirm the expression of the transgene at the
protein level (Figure 2). All tested transgenic lines produced
both the BLC and BHC proteins (Figures 2A,B). Transgenic
lines with transgenes expressed in two expression cassettes
(Figure 2A) produced variable levels of BLC (∼25 kDa) and BHC
(∼50 kDa), and in most lines signals of expressed BLC were
stronger than the BHC. The ratios of BLC to BHC in different
transgenic lines were from 0.95 to 19.2 with an average of 4.32
6http://www.expasy.org/tools/peptide-mass.html
(Supplementary Table S1), indicating unbalanced expression of
the BLC and BHC proteins. Thus, further analysis of transgenic
lines with this construct was not performed.
In contrast, BLC and BHC in most transgenic lines with the
2A peptide constructs were proportional, although variations in
the expression levels were observed among different transgenic
events. The BLC:BHC ratios from different transgenic lines
were from 0.11 to 1.90 with an average of 0.99, similar to the
ratio of the commercial Bevacizumab (Avastin) sample (0.99)
(Supplementary Table S1), indicating that about equal molecules
of BLC and BHC peptides were produced by the self-cleavage of
2A peptide linker (Figure 2B). In all transgenic lines, there were
only two major bands of the ∼25 kDa BLC and the ∼50 kDa
BHC, indicating that he self-cleavage of the 2A peptide was
complete and the majority of expressed protein was intact with
little degradation.
To find out whether the expressed BLC and BHC had
assembled correctly into mAb tetramers, a non-reducing SDS-
PAGE that would not disrupt disulphide bonds of the antibody
was performed (Figure 2C). Five transgenic lines transformed
with the pUNBevaHL and four lines with the pUNBevaHL-
KDEL expressed comparable levels of mAb with a molecular
weight of about 150 kDa, similar to the positive control of the
commercial Bevacizumab. In all transgenic lines, there was only
one ∼150 kDa band of the mAb, indicating that there was no
protein degradation.
Biological Activity and Quantification of
Rice-derived Bevacizumab mAb
The finding that transgenic rice callus could produce correctly
assembled mAb tetramers indicated that this plant expressed
mAb could be functional. Biological activity of rice-derived
Bevacizumab was detected by ELISA, an assay based on the highly
specific antigen–antibody interaction. The interactions of rice-
expressed Bevacizumab to hVEGF were confirmed in all four
tested transgenic lines, similar to the positive control, but no
interaction was detected when the non-transgenic rice was used
as a negative control (Figure 3A).
Quantification of the mAb was performed by comparing the
OD450 reading of each sample to a standard curve produced by
a commercial Bevacizumab (Avastin) standard (Figure 3B). The
Bevacizumab contents in four selected transgenic lines were from
160.7 to 242.8 mg/Kg FW (Figure 3C).
Extraction and Purification of mAb
Expressed in Transgenic Rice Callus
MAbs from two transgenic lines (UNBevaHL-3-15 and
UNBevaHL-KDEL-5) were purified by Protein A affinity
chromatography from 50 g of callus material from each
transgenic line. 135.1 and 101.1 mg/Kg FW mAbs were recovered
from the two transgenic lines, corresponding to a recovery rate of
55.6 and 59.8%, respectively (Table 1). The purities of the mAbs
were detected by running purified samples on a SDS-PAGE,
which showed mainly the ∼150 kDa mAb band. However, weak
lower molecular weight bands were observed when 5 µg proteins
(lanes 1 and 2) were loaded (Figure 4).
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FIGURE 2 | Western blot of the expression of BHC, BLC, and Bevacizumab mAb in transgenic rice callus. The BLC, BHC, and Bevacizumab mAb were
detected with a goat anti-human IgG (LC and HC) antibody under reducing (A,B) and non-reducing conditions (C). (A) BHC and BLC were expressed from different
gene expression cassette, (B,C) BHC and BLC were expressed as a polyprotein separated with the 2A peptide. PC is a positive control with a commercial
Bevacizumab mAb; NC is a negative control with the total soluble proteins from non-transformed callus; lanes 1–8 in (A), 1–5 and 6–9 in (B,C) are total soluble
proteins from different transgenic events transformed with pUNBHLC, pUNBevaHL, and pUNBevaHL-KDEL, respectively. Protein molecular weights are indicated on
the left side of each panel. BHC (50 kDa), BLC (25 kDa), and mAb (150 kDa) are indicated on the right side of each panel.
Affinity Determination of Rice-derived
Bevacizumab by ELISA
To compare the binding affinity of the rice-derived mAbs
with the commercial Bevacizumab to VEGF, an ELISA was
performed with the two mAbs with and without the KDEL
ER retention signal purified from rice callus (Table 1) and a
commercial Bevacizumab control. As shown in Figure 5, there
was no significant difference in binding affinity between the
two Bevacizumab produced from rice callus with or without
the KDEL signal peptide, and no significant difference was
detected between the rice-derived mAbs to the commercial
Bevacizumab.
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FIGURE 3 | Functional analysis of plant expressed Bevacizumab mAb
and qualification of the expression levels in transgenic plants by
ELISA. (A) The binding activity of rice-derived Bevacizumab to hVEGF antigen
was determined by ELISA with a positive control of the commercial
Bevacizumab mAb and a negative control of non-transformed plants. Two
transgenic lines each from pUNBevaHL and pUNBevaHL-KDEL transformed
plants were analyzed in triplicates. (B) Standard curve of Bevacizumab.
(C) mAb expression levels in transgenic plants. The experiment was
performed in triplicates, and the means and errors of mAb contents in different
transgenic plants were presented in graph.
N-glycan Analysis of Rice-derived
Bevacizumab
Tryptic digested glycopeptides from two rice-derived
Bevacizumab mAbs differing in the KDEL ER retention
signal peptide were analyzed by liquid chromatography tandem
mass spectrometry (Table 2; Supplementary Figure S3). Both
mAbs had high percentages of plant-specific glycosylation with
TABLE 1 | Recovery of Bevacizumab mAb expressed in transgenic rice
callus.
UNBevaHL-3-15 UNBevaHL-KDEL-5
Fresh callus weight (g) 50 50
mAb yield (mg/Kg FW) 135.1 101.1
mAb content in callus (mg/Kg FW) 242.8 169.1
Recovery rate (%) 55.6 59.8
β1, 2-xylose and α1, 3-fucose. The total percentages of plant-
specific glycosylation including MMXF (M3Gn2X1F1), GnMXF
(M3Gn3X1F1), and GnGnXF (M3Gn4X1F1) were 56.7% for
mAb without the KDEL peptide and 46.8% for that with
KDEL. Other forms of glycosylation including high mannose
types, Man3 (M3Gn2), Man4 (M4Gn2), Man5 (M5Gn2), Man6
(M6Gn2), Man7 (M7Gn2), Man8 (M8Gn2), and Man9 (M9Gn2),
paucimannosidic glycans as well as non-glycosylation were also
observed in both mAbs produced in transgenic rice callus.
DISCUSSION
In this report, we designed and expressed a biologically
functional mAb (Bevacizumab) in transgenic rice callus. The
plant expression system has many advantages including high-
level productivity, easy management and scaling-up, safety and
low cost. To maximize the benefit of the plant expression system,
many strategies have been developed to improve the expression
and to increase the production. For example, transgenes can be
stably integrated into the nuclear genome or transiently expressed
using viral or Agrobacterium vectors (Vaquero et al., 1999;
Kathuria et al., 2002; Rodriguez et al., 2005; Sainsbury et al.,
2008; Villani et al., 2009). In addition, stable expression in cell
cultures can produce uniform recombinant proteins in controlled
environments by using bioreactors so that good manufacturing
practice (GMP) can be applied (Shih and Doran, 2009; Xu et al.,
2011; Huang and McDonald, 2012). In this study, we produced
bioactive Bevacizumab in stably transformed rice callus and
the rice-derived Bevacizumab content reached 242.8 mg/Kg FW
(Figure 4). With the development of the rice suspension culture
system, it is possible to scale up the production to reach large-
scale production by using the bioreactor technology such as the
continuous or semi-continuous production system to reduce the
production time and manufacturing cost (Tekoah et al., 2015;
Yang et al., 2015; Corbin et al., 2016).
The complete mAb consists of two identical LCs and HCs
connected by disulfide bonds. Low-level expression of mAbs in
previous reports was mostly affected by the expression strategies.
Unbalanced expression of the LC and HC was unavoidable in
the previous systems when the two genes coding for the LC and
HC were expressed separately, or expressed in one bicistronic
mRNA separately by the IRES because the downstream open
reading frame (ORF) was only expressed at ∼10% level of the
upstream one (Minskaia and Ryan, 2013; Minskaia et al., 2013).
Unbalanced expression of LC and HC is unfavorable to the
yield and quality of mAb production because efficient assembly
and modification of mAb seem to require an optimal ratio
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FIGURE 4 | SDS-PAGE of purified Bevacizumab mAb in transgenic
rice. 5 µg (lane 1), 2 µg (lane 3), and 1 µg (lane 5) mAbs purified from
pUNBevaHL transformed rice callus, 5 µg (lane 2), 2 µg (lane 4), and 1 µg
(lane 6) mAbs purified from pUNBevaHL-KDEL transformed rice callus, and
0.5 µg commercial Bevacizumab mAb (lane 7) were analyzed by
non-reducing SDS-PAGE and stained with Coomassie blue. The major
150 kDa mAb band was indicated.
FIGURE 5 | Bevacizumab binding activity to VEGF measured by ELISA.
Purified Bevacizumab mAbs from transgenic rice callus with the
pBevaHL-KDEL construct (green square) and the pBevaHL construct (red
diamond), a commercial Bevacizumab (blue triangle, positive control), and 1×
PBS buffer without Bevacizumab (purple dot, negative control) were analyzed
by ELISA for binding activities to hVEGF. Each measurement was performed
in triplicates.
of LC and HC (Schlatter et al., 2005; Ho et al., 2013b; Chng
et al., 2015). However, contradictory results were reported on the
optimal ratio of LC and HC in recombinant mAb production.
Excessive expression of LC was considered to be beneficial for
mAb production because excess LC would allow more efficient
mAb folding, assembly, and the clearance of HC, which is prone
to aggregation when expressed in excess (Vanhove et al., 2001;
Lee et al., 2009). Ho et al. (2013b) reported higher titers of
mAb production at a LC:HC ratio of 3.43. Similarly, Schlatter
et al. (2005) observed efficient production of three mAbs with
LC:HC peptide ratios of 2, 2.5, and 3.1 in CHO cells. On the
contrary, separate groups also reported that excessive HC was
TABLE 2 | Mass spectrometric analysis of glycopeptides from purified
mAb after tryptic digestion.
Glycoform Relative abundance (%)
pUNBevaHL pUNBevaHL-KDEL
Non-glycosylated 2.7 10.8
Single GlcNAc (Gn) 16.3 26.1
Man3 (M3Gn2) 9.4 1.6
Man4 (M4Gn) 1.9 1.2
Man5 (M5Gn2) 2.3 1.9
Man6 (M6Gn2) 1.7 1.6
Man7 (M7Gn2 2.6 2.4
Man8 (M8Gn2) 4.0 5.7
Man9 (M9Gn2) 2.4 1.9
MMXF (M3Gn2X1F1) 19.4 14.6
GnMXF (M3Gn3X1F1) 7.6 5.1
GnGnXF (M3Gn4X1F1) 29.7 27.1
GlcNAc, N-acetylglucosamine (Gn); F, fucose; Man, mannose (M); X, xylose.
beneficial to IgG expression (Jiang et al., 2006; Fallot et al., 2009).
However, excessive expression of either LC or HC produced LC
or HC dimmer and monomer molecules besides the LC2HC2
mAb (Ho et al., 2013b). Unlike the other systems, using of 2A self-
cleavage peptide can ensure equal molars expression of LC and
HC peptides to avoid unbalanced expression, and thus produce
high levels of mAbs (Chng et al., 2015).
The FMDV RNA genome contains a single ORF, which
encodes a polyprotein. The FMDV 2A peptide between the 2A
and 2B regions of the polyprotein is self-cleaved to produce the
viral 2A and 2B proteins (Ryan et al., 1991). The self-cleavage of
2A peptide is co-translational by a “Stop-Go” or “Stop-carry on”
recoding mechanism, by which the upstream protein translation
is paused by the 2A sequence and the peptide backbone is broken
between the last two amino acids, Glycine (G) and Proline (P) of
the 2A peptide (Atkins et al., 2007; Doronina et al., 2008; Sharma
et al., 2011). The 2A peptide also drives a translational recoding
of the downstream protein. Unlike other systems, 2A peptide-
mediated cleavage is not dependent on cellular factors in different
cell types because the self-cleavage activity is only dependent
on the ribosomes, which are structurally conserved among all
eukaryotic organisms. Thus, the 2A peptide is active in all
eukaryotic systems, and has been used widely as a co-expression
tool in the expression of two or more proteins (Donnelly et al.,
2001; de Felipe et al., 2006). Recently, 2A peptide was applied
in stable and high levels expression of mAbs in CHO cells and
mice, and was considered to have potential applications of in vivo
delivery of mAbs in gene therapy (Fang et al., 2005; Chng et al.,
2015). 2A peptide was also applied in the production of a single
chain antibody in plants (Smolenska et al., 1998). However, the
application of 2A in the production of complete mAb in plants
has not been reported so far.
We reported the expression of a mAb (Bevacizumab) LC
and HC as a polyprotein with the 2A linker from FMDV in
one gene expression cassette driven by a strong constitutive
ubiquitin promoter in transgenic rice callus. High levels of
functional antibodies were produced (Figure 3). We achieved
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the expression of more than 200 mg/Kg FW of Bevacizumab
mAb in transgenic rice cells, which was higher than most of the
reported recombinant mAb expression systems (Gomord et al.,
2004; Girard et al., 2006; Villani et al., 2009; De Muynck et al.,
2010; Madeira et al., 2015). The high levels of expression could be
attributed to the following factors. First, the codon optimization
makes the mRNA stable and the protein translation efficient.
Second, a strong constitutive ubiquitin promoter increases the
transgene transcription level. Third, single copy transgene by the
Agrobacterium-mediated transformation reduces the chances of
gene silencing. Last but not least, the expression of a polyprotein
using 2A self-processing peptide favors the accumulation of
functional mAb. The using 2A peptide expression system may
affect the mAb yield by the following ways. First, the self-cleavage
of 2A linked polyprotein produces equal molecules of HC and
LC, which might be an optimal ratio for mAb accumulation.
Western blot revealed that the LC and HC of Bevacizumab
expressed with 2A polypeptide were at similar levels in most
transgenic lines, but unbalanced expressions of LC and HC
were observed when they were on different expression cassettes
(Figure 3). Although the excess of either LC or HC might speed
up the mAb assembly as shown in a mathematical modeling
(Gonzalez et al., 2002), a 1:1 LC:HC ratio is more economical
because IgG mAbs have equal numbers of LC and HC subunits.
Second, the self-cleavage is co-translational, so that both the LC
and HC are simultaneously produced and mobilized into ER,
where mAb can be immediately assembled and folded. Third,
correct and complete assembly of mAb may reduce proteolytic
degradation of either LC or HC monomers or dimmers when
present in excess because incorrectly or incompletely folded
antibodies are susceptible to protease attack (Gardner et al.,
1993). Post-translational protein degradation has been a common
phenomenon that significantly influences the yield of foreign
protein production (Doran, 2006; De Muynck et al., 2010;
Desai et al., 2010; Xu et al., 2011; Hehle et al., 2016). But,
the degradation of mAb was not observed in our studies based
on the Western blot results. This is probably because of the
correct and complete assembly of mAb from LC and HC subunits
generated from the 2A self-cleavage polyprotein (Figure 2C).
The weak lower molecular weight bands observed in Figure 4
were probably degradation products during the process of protein
extraction and purification because such bands were not observed
before this process (Figure 2C).
Glycosylation is an important property of recombinant mAb
that affects its binding affinity and circular half-life, and causes
immunogenicity (Saint-Jore-Dupas et al., 2007; Reusch and
Tejada, 2015). It has been shown that plant expressed proteins
are differently modified as compared to mammalian systems. The
plant-specific glycosylation including the β 1, 2-xylose and a core
α 1, 3-fucose takes place in the Golgi apparatus. To avoid plant-
specific glycosylation, two strategies are generally used: to keep
the recombinant protein in the ER with an ER retention signal
peptide or to knockout plant genes coding the plant-specific
glycosylation enzymes by glycoengineering (Strasser et al., 2008,
2014; Castilho and Steinkellner, 2012; Castilho et al., 2014;
Kurogochi et al., 2015). In this report, we tried to target both
the HC and LC to ER by adding KDEL signal peptides at the
C-termini, but were unsuccessful in preventing the plant-specific
glycosylation (Table 2), indicating that the KDEL signals were
not functioning properly. One reason for this malfunction of the
KDEL signal could be related to results of the self-processing of
the 2A peptide linker between the HC and LC. It was reported
that the cleavage of the 2A peptide between the last two amino
acids, Glycine (G) and Proline (P) would result in the adding
of a GSGQLLNFDLLKLAGDVESNPG peptide to the C-terminal
of the upstream protein and a P amino acid residue to the
N-terminal of the downstream one (Chng et al., 2015). In our
design (Figure 1), the adding of the 2A peptide to the C-terminal
of the HC would abolish the KDEL signal, which only functions
when present at the C-terminal of a protein. The loss of KDEL
signal in upstream protein can be solved by adding a furin
protease recognition site upstream of 2A, which will remove
the residues of the 2A peptide (Chng et al., 2015). Although
this strategy can solve the ER retention problem in future
studies, the retention of recombinant mAb in ER with the KDEL
signal will limit the protein secretion and invariably increase
the downstream process cost. Thus, an alternative approach
by glycoengineering to silence or knockout the plant-specific
glycosylation genes and to introduce mammalian glycosylation
genes into plants could be a better solution (Strasser et al., 2008,
2014; Castilho and Steinkellner, 2012).
Glycosylation affects the antibody-dependent cell-mediated
cytotoxicity (ADCC) of recombinant mAbs. For example, fucose-
free mAb (13F6) produced in glycoengineered tobaccos was
demonstrated to have higher binding affinity to FcγR and
enhanced potency against Ebola virus (Zeitlin et al., 2011).
However, Bevacizumab functions through the binding and
neutralization of secreted VEGF, but lacks the ADCC (Wang
et al., 2004). The biological activity of rice-derived Bevacizumab
mAb (including KDEL tagged and non-tagged) was analyzed by
an ELISA-based binding assay to its hVEGF antigen (Figure 5).
No significant difference was observed between the two rice
expressed mAbs and between the rice expressed mAb and
the commercial Bevacizumab control, indicating that the rice
expressed Bevacizumab mAb is functional. It remains unknown
if the rice expressed Bevacizumab mAb have other comparable
properties such as the neutralization of hVEGF in vivo, the
circular half-life in clinical studies, and most importantly the
adverse immunogenicity related to plant expressed recombinant
proteins, which need to be characterized in future studies.
In conclusion, we reported an efficient recombinant mAb
expression system in transgenic rice callus using the FMDV
2A self-cleavage peptide. The cleavage of 2A peptide linked
polyprotein in one gene expression cassette produced equal
molecules of HC and LC of a mAb, allowed efficient assembly and
folding of functional antibody, and produced recombinant mAb
at high levels.
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